Baird downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a $132 price target after Johnson & Johnson (JNJ) agreed to acquire all outstanding shares of Intra-Cellular for $132 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald
- Intra-Cellular downgraded to Hold from Buy at Needham
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue